Revolution Medicines D
D
RVMD
172.280
USD
-4.01
(-2.27%)
Post Trading·172.020USD-0.260(-0.15%)
Last updated: · Delayed 15 min
Revolution Medicines earningsWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
Revolution Medicines reports its Q4 FY2026 results on 24 February 2027, after the market closes. Analysts expect earnings per share of -1.22 USD and revenue of 388.66M USD.
In Q3 FY2026, reported on 4 November 2026, Revolution Medicines reported EPS of -1.90 USD against the -2.35 USD analysts expected (+19.1%), on revenue of 197.60M USD against 25.58M USD (+672.4%).
- Last EPS surpriseWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +19.1%
- Last revenue surprise
- +672.4%
- Move after the last reportWhat is the next-day move after earnings? The next-day move is how much a stock's price changed on the first trading day after an earnings report: how the market took the results.
- -10.9%
- Average move after earningsWhat is the next-day move after earnings? The next-day move is how much a stock's price changed on the first trading day after an earnings report: how the market took the results.
- 4.2%
EPS and revenue against estimates
Next earnings · Q4 FY2026
EPS estimate
-1.22 USD
Revenue estimate
388.66M USD
Last quarter · Q3 FY2026
EPS-1.90Beat +19.1%Revenue197.60MBeat +672.4%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth | Next-day move |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3 FY2027 | -0.49 | — | — | — | 596.25M | — | — | +201.75% | — | |
| Q2 FY2027 | -0.66 | — | — | — | 522.96M | — | — | +29,392.47% | — | |
| Q1 FY2027 | -0.85 | — | — | — | 443.74M | — | — | +18,198.46% | — | |
| Q4 FY2026 | -1.22 | — | — | — | 388.66M | — | — | +10,467.83% | — | |
| Q3 FY2026 | -2.35 | -1.90 | +19.15% | — | 25.58M | 197.60M | +672.44% | +11,615.41% | -10.9% | |
| Q2 FY2026 | -2.04 | -3.06 | -50.00% | — | 1.77M | — | — | -93.56% | +0.5% | |
| Q1 FY2026 | -1.84 | -2.29 | -24.46% | — | 2.43M | — | — | +102.08% | -5.7% | |
| Q4 FY2025 | -1.58 | -1.86 | -17.72% | — | 3.68M | — | — | +880.74% | -1.0% | |
| Q3 FY2025 | -1.42 | -1.61 | -13.38% | — | 1.69M | — | — | +387.26% | +3.6% | |
| Q2 FY2025 | -1.14 | -1.31 | -15.11% | — | 27.53M | — | — | +3,308.48% | -4.6% | |
| Q1 FY2025 | -1.12 | -1.13 | -0.89% | — | 1.20M | — | — | -12.58% | +11.3% | |
| Q4 FY2024 | -1.01 | -1.12 | -10.89% | — | 375.00K | — | — | -49.46% | -3.4% | |
| Q3 FY2024 | -0.89 | -0.94 | -5.62% | — | 346.15K | — | — | -53.85% | -0.7% | |
| Q2 FY2024 | -0.77 | -0.81 | -5.19% | — | 807.69K | — | — | -78.88% | -0.5% | |
| Q1 FY2024 | -0.75 | -0.70 | +6.67% | — | 1.37M | — | — | -80.43% | -2.2% | |
| Q4 FY2023 | -0.88 | -1.14 | -29.55% | — | 666.67K | 742.00K | +11.30% | -95.16% | +0.7% | |
| Q3 FY2023 | -1.01 | -0.99 | +1.98% | — | 750.00K | — | — | -77.65% | — | |
| Q2 FY2023 | -0.82 | -0.92 | -12.20% | — | 1.56M | 3.82M | +144.74% | -58.05% | — | |
| Q1 FY2023 | -0.81 | -0.72 | +11.11% | — | 3.39M | 7.01M | +106.88% | -7.44% | — | |
| Q4 FY2022 | -0.82 | -0.63 | +23.17% | — | 7.80M | 15.33M | +96.47% | +62.05% | — | |
| Q3 FY2022 | -0.84 | -0.87 | -3.57% | — | 6.34M | 3.36M | -47.04% | +204.81% | -0.6% | |
| Q2 FY2022 | -0.85 | -0.82 | +3.53% | — | 7.02M | 9.12M | +29.89% | +4.81% | +2.7% | |
| Q1 FY2022 | -0.77 | -0.78 | -1.30% | — | 8.58M | 7.58M | -11.71% | -25.20% | +6.1% | |
| Q4 FY2021 | -0.64 | -0.71 | -10.94% | — | 8.99M | 9.46M | +5.23% | +8.10% | -1.8% | |
| Q3 FY2021 | -0.63 | -0.72 | -14.29% | — | 923.42K | 1.10M | +19.23% | -91.30% | +0.9% | |
| Q2 FY2021 | -0.56 | -0.60 | -7.14% | — | 8.70M | 8.70M | 0.00% | -13.24% | -11.1% | |
| Q1 FY2021 | -0.52 | -0.53 | -1.92% | — | 9.94M | 10.13M | +1.96% | -12.26% | +6.6% | |
| Q4 FY2020 | -0.38 | -0.52 | -36.84% | — | 16.78M | 8.75M | -47.85% | -30.03% | -5.7% | |
| Q3 FY2020 | -0.39 | -0.42 | -7.69% | — | 11.69M | 12.66M | +8.33% | — | +5.3% | |
| Q2 FY2020 | -0.36 | -0.46 | -27.78% | — | 7.85M | 10.03M | +27.78% | -18.37% | +9.2% | |
| Q1 FY2020 | -0.33 | -0.74 | -124.24% | — | 10.39M | 11.55M | +11.11% | — | -5.2% | |
| Q4 FY2019 | -0.41 | -6.52 | -1,490.24% | — | — | 12.09M | — | +16.83% | -1.8% | |
| Q4 FY2019 | — | -0.35 | — | — | — | 12.51M | — | +20.87% | -3.1% | |
| Q2 FY2019 | — | -0.28 | — | — | — | 12.28M | — | — | — | |
| Q4 FY2018 | — | -0.28 | — | — | — | 13.17M | — | — | — | |
| Q4 FY2018 | — | -0.31 | — | — | — | 10.35M | — | — | — |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 0.66 | — | — | — | 3.36B | — | — | +68.13% |
| FY2027 | -2.95 | — | — | — | 2.00B | — | — | +251.90% |
| FY2026 | -8.51 | — | — | — | 568.29M | — | — | +16,210.40% |
| FY2025 | -5.65 | -5.91 | -4.65% | — | 3.48M | — | — | +1,061.40% |
| FY2024 | -3.47 | -3.57 | -2.80% | — | 300.00K | — | — | -97.63% |
| FY2023 | -3.48 | -3.77 | -8.41% | — | 12.65M | — | — | -64.24% |
| FY2022 | -3.29 | -3.10 | +5.83% | — | 27.86M | 35.38M | +26.98% | +20.38% |
The move is the shares' change on the trading day after the report: after a report after the close, the next day's close on the report day's; before the open, the report day's close on the day before's. Surprise is the reported figure against the analysts' average estimate.
Beat recordWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 16.6% off the result, either way, and their revenue estimate 341.9%, over the last 12 quarters.
- EPS beats
- 6 / 28
- Revenue beats
- 12 / 16
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- -12.2%
- Since
- March 2020
See also:Forecast,EPS,Income statement
Common questions about Revolution Medicines's earnings
Source: Financial Modeling PrepVerified against SEC filings